Furthermore, targeting of the CoREST complex with the small-molecule inhibitor corin led to increased expression of DUSP1, inhibition of p38 MAPK activity, and resensitization of BRAF-resistant melanomas to BRAFi therapy. This evidence concerns the gene RCOR1 and melanoma.